Table 4.
The use of ruxolitinib and upadacitinib in treating autoimmune bullous disease.
| Age/ gender |
Types of AIBD | Complica-tion | Previous therapies | Treatment | Efficacy of initial JAK inhibitors | Tapering of JAK inhibitors | Efficacy of maintenance treatment | AE | Relapse | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fan et al., 2022 (60) | 31/F | PNP | Castleman’s disease | Prednisolone, cyclosporine, azithromycin | Ruxolitinib 5mg/d, prednisolone 10mg/d, cyclosporine 100mg/d |
The symptoms were improved. | NA | Clinical presentation and laboratory tests improved. | NA | None |
| Gresham et al., 2023 (61) | 74/F | DIBP | SCCHN, malignant melanoma | Prednisone, TCS | Upadacitinib, 15 mg/d | The patient demonstrate response to upadacitinib | NA | NA | NA | NA |
| Nash et al., 2023 (62) | 81/F | BP | HT, dyslipidemia, osteoarthritis, endometriosis | Prednisone | Upadacitinib, 15 mg/d, prednisone |
Complete resolution of disease. | NA | Continued efficacy with further healing of the skin and complete resolution of the disease. | None | None |
AIBD, autoimmune bullous disease; AE, adverse effect; PNP, paraneoplastic pemphigus; DIBP, drug-induced bullous pemphigoid; BP, bullous pemphigoid; SCCHN, squamous cell carcinoma of the head and neck; HT, hypertension; TCS, topical corticosteroids; M, male; F, female; NA, not available; mg/d, mg/day.